Evidence map›Paper›PMID 34765725›Full record

ArticleMedical research archives2021

Inference of Sojourn Time and Transition Density using the NLST X-ray Screening Data in Lung Cancer.

Farhin Rahman, Dongfeng Wu

Open access · diamondAbstract read
In one paragraph

Article in Medical research archives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Farhin RahmanDepartment of Bioinformatics and Biostatistics, University of Louisville, KY, USA.
Dongfeng WuDepartment of Bioinformatics and Biostatistics, University of Louisville, KY, USA.
University of Louisville · US

Funding

Dynamic scheduling of the upcoming screening exam based on screening history and other parametersR15CA242482 · NCI · UNIVERSITY OF LOUISVILLE · PI WU, DONGFENG · 2019 to 2019
$435k
NCI NIH HHS R15 CA242482
6 · The paper itself

Abstract

aimsThe aim of this study is to provide statistical inference of the sojourn time and the transition probability from the disease free to the preclinical state of lung cancer for male and female smokers using lung cancer data from the National Lung Screening Trial (NLST). MATERIALS AND

methodsWe applied a likelihood function to the lung cancer data, to obtain Bayesian inference of the transition probability and the sojourn time distribution. A log-normal distribution was used for the transition probability density function multiplied by 30%, and a Weibull distribution was used to model the sojourn time in the preclinical state.

resultsThe estimate of screening sensitivity is 0.61 for males and 0.62 for females. Early transition happened before age 50 and lasted until after age 90. The transition probability from the disease free to the preclinical state has a single maximum at around age 73 for males and 72 for females. For male, the Bayesian posterior mean, and median sojourn time are 1.33 and 1.27 years, respectively. For female, the corresponding posterior mean, and median sojourn time are 1.23 and 1.21 years, respectively.

conclusionOur estimation showed that male smokers are more vulnerable to lung cancer, because they have a higher transition probability density than the same aged female smokers. The female smokers have a slightly shorter mean sojourn time than the male, meaning that they are quicker to develop clinical symptom of lung cancer.

Indexed as

Lung Cancer ScreeningMarkov Chain Monte CarloNational Lung Screening TrialSensitivitySojourn TimeTransition Density

Identifiers

PMID34765725
PMCPMC8580138
OpenAlexW3165142823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.